Follow the Lupin Limited share price and the full directors' dealings record of the company, a publicly traded company based in India. Shares are quoted on the IN market, under the oversight of SEBI (PIT + SAST). Operating in the Health Care sector, Lupin Limited has recorded 30 reports. Market capitalisation: €1,107.1bn. The latest transaction was filed on 8 September 2021 (Sale). Among the most active insiders: Naresh Kumar Gupta. Every trade is accessible without an account.
30
Insider Decl.
n/a
Thresholds
€478,585
7 ops.
Buy Volume
€1m
23 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Lupin Limited Buy (bullish), based on 37 analysts. Average price target: ₹2,488.68.
10Σ signal
Buys €478,585€1m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 4,269 of 28,856 companies
70.2
score / 100
Value
57
Quality
84
FCF yld4.8%
Earn yld4.8%
EV/EBITDA13.5x
ROE27%
Gross mgn70%
Net mgn19%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
200 shares@ ₹1,208.900.0000% mcap3.2% of flowEquity SharesSEBI:8cff36e0bc543e11f0cb47729a597198d92c005c
25 of 30 declarations
About Lupin Limited
Lupin Limited is an Indian pharmaceutical company focused on the research, development, and manufacturing of generic drugs and pharmaceutical products. It is listed on the Bombay Stock Exchange under the symbol XBOM.